Parametric Portfolio Associates LLC raised its position in shares of Omeros Corporation (NASDAQ:OMER) by 156.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 68,935 shares of the biopharmaceutical company’s stock after purchasing an additional 42,084 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.16% of Omeros Corporation worth $1,372,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Omeros Corporation by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock valued at $36,341,000 after purchasing an additional 94,280 shares during the period. Northern Trust Corp boosted its holdings in shares of Omeros Corporation by 6.4% during the 2nd quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after buying an additional 34,328 shares in the last quarter. Quantitative Investment Management LLC bought a new position in shares of Omeros Corporation during the 2nd quarter worth approximately $2,979,000. Ameriprise Financial Inc. bought a new position in shares of Omeros Corporation during the 2nd quarter worth approximately $971,000. Finally, TIAA CREF Investment Management LLC boosted its holdings in shares of Omeros Corporation by 39.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 149,252 shares of the biopharmaceutical company’s stock worth $2,971,000 after buying an additional 42,165 shares in the last quarter. 45.37% of the stock is owned by institutional investors and hedge funds.
OMER has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a “hold” rating and set a $19.00 price target (up from $15.00) on shares of Omeros Corporation in a report on Thursday, August 24th. Zacks Investment Research cut Omeros Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Maxim Group set a $24.00 price target on Omeros Corporation and gave the stock a “buy” rating in a report on Friday, October 20th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a report on Friday, August 18th. Finally, HC Wainwright initiated coverage on Omeros Corporation in a report on Wednesday, November 8th. They set a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $34.14.
Omeros Corporation (OMER) opened at $18.97 on Wednesday. Omeros Corporation has a twelve month low of $8.71 and a twelve month high of $27.09. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77.
Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to the consensus estimate of $17.82 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. Omeros Corporation’s revenue for the quarter was up 91.9% on a year-over-year basis. equities research analysts anticipate that Omeros Corporation will post -1.32 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://weekherald.com/2017/11/15/omeros-corporation-omer-holdings-increased-by-parametric-portfolio-associates-llc.html.
Omeros Corporation Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.